Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 305 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

NCT03103750
Conditions
ADHD
Interventions
Magnetic Resonance Imaging (MRI), PHNO, calcitriol, Placebo oral capsule, high-resolution research tomography, Dextro Amphetamine
Procedure · Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Interventions
Xanomeline and trospium chloride (KarXT)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine in Schizophrenia

NCT01104779
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Costa Mesa, California • Long Beach, California • Paramount, California + 12 more
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa capsules, Placebo capsules
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
168
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

NCT04493320
Conditions
Depression, Cognitive Impairment, Gait Impairment
Interventions
Carbidopa/levodopa, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

PET Study Examining the Dopaminergic Activity of Armodafinil in Adults

NCT00592943
Conditions
Healthy
Interventions
armodafinil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Developmental Stuttering
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Parkinson Disease
Interventions
Autologous midbrain dopamine neurons
Biological
Lead sponsor
Penelope J. Hallett, Ph.D.
Other
Eligibility
55 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
[11C]NNC-112
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson Disease
Interventions
Ropinirole oral product, Ropinirole Implant
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington
Conditions
Hyperaldosteronism, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1981 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Dopamine Function and Reward Processing In Schizophrenia

NCT01035996
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Heart Failure
Interventions
Inotrope
Drug
Lead sponsor
Coram Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 1 more
Conditions
Amphetamine-Related Disorders, Tobacco Use Disorder
Interventions
radioactive substance
Procedure
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational Accepts healthy volunteers

PET Scan in Patients With Neurocardiologic Disorders

NCT00001418
Conditions
Autonomic Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers

Neural Correlates of Acute Pain Dynamics

NCT05669924
Conditions
Pain
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Not applicable Interventional Accepts healthy volunteers

Monetary Incentive Delay Task for Probing Reward-related Neural Processes

NCT06369623
Conditions
Adolescent Development
Interventions
Monetary Incentive Delay Task
Other
Lead sponsor
Stony Brook University
Other
Eligibility
14 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Depression
Interventions
Pramipexole (Mirapex), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Effects of Kuvan on Melatonin Secretion

NCT01617070
Conditions
Phenylketonuria (PKU)
Interventions
Kuvan, Large Neutral Amino Acid Therapy
Drug · Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Parkinson's Disease, Dyskinesias
Interventions
Intravenous Levodopa, ACP-103
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

NCT04128683
Conditions
Anorexia Nervosa
Interventions
amisulpride, bromocriptine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California